TELATHA SURUJNATH: Open Payments
NPI 1588009047 · LAKEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,824 in 155 payments from 15 companies in 2025. Trend: 2023 $1,222 · 2024 $1,467 · 2025 $1,824
Food & beverage: $1,824
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $452 |
| Neurocrine BioSciences, Inc. | 30 | $263 |
| Otsuka America Pharmaceutical, Inc. | 21 | $203 |
| Axsome Therapeutics, Inc. | 16 | $183 |
| E.R. Squibb & Sons, L.L.C. | 16 | $160 |
| Alkermes, Inc. | 14 | $135 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| Supernus Pharmaceuticals, Inc. | 5 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Neos Therapeutics, LP | 3 | $54 |
Products named: VRAYLAR, INGREZZA, REXULTI, COBENFY, Auvelity, LYBALVI, AUSTEDO XR, Sunosi.
Industry payments across NJ — which companies pay providers there.
